bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 13.20M |
| Revenue (ttm) | 7.68M |
| Net Income (ttm) | -11.69M |
| Shares Out | 4.49M |
| EPS (ttm) | -20.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 702,621 |
| Open | 3.200 |
| Previous Close | 3.410 |
| Day's Range | 2.940 - 3.220 |
| 52-Week Range | 2.340 - 67.116 |
| Beta | 2.34 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 13, 2025 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have... [Read more]
Financial Performance
In 2024, bioAffinity Technologies's revenue was $9.36 million, an increase of 269.68% compared to the previous year's $2.53 million. Losses were -$9.04 million, 13.9% more than in 2023.
Financial StatementsNews
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AI--The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies received written notice from Nasdaq stating that the Company has regained compliance with continued listing requirements.
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J. , Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc...
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed on a $1.8 million registered direct offering of common stock.
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J. , Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc...
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces a $1.8 million registered direct offering of common stock.
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the previous quarter.
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
JERSEY CITY, N.J. , Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I...
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes $4.8 million public offering.
WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
JERSEY CITY, N.J. , Sept. 29, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I...
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $4.8 million public offering.
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures.
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced it will effect a 1-for-30 reverse split of its common stock at the opening of trading on September 19, 2025.
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CyPath® Lung identifies incidentally found ground-glass lung nodules, leading to early diagnosis and timely treatment.
bioAffinity Technologies Appoints New Members to Board of Directors
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies appoints leaders in corporate finance and the diagnosis and treatment of asthma and COPD to its Board of Directors.
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes private placement and warrant inducement transaction for approximately $1.2 million in gross proceeds.
bioAffinity Technologies Reports Second Quarter 2025 Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports Q2 2025 results; CyPath Lung revenues up 62% year-over-year in first six months of 2025.
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of private placement and warrant inducement transaction.
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a significant surge in commercial sales of CyPath® Lung with back-to-back record monthly sales in June and July.
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CyPath® Lung detects a rare mucinous adenocarcinoma at Stage 1A in a high-risk individual whose previous tests suggested a low probability of cancer.
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Canada grants bioAffinity Technologies new patent that protects its proprietary technology that powers its flagship product, CyPath® Lung.
bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies has received notification of allowance from China for a patent on its technology for predicting the likelihood of lung cancer.
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity scientists present breakthrough research on using siRNAs to knock down two receptors on the cell membrane to selectively kill cancer cells.
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--China has issued a notification of patent grant to bioAffinity for its novel method of using siRNAs to selectively kill cancer cells.
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board
SAN ANTONIO--(BUSINESS WIRE)-- #ALA--bioAffinity CEO Maria Zannes joins the American Lung Association in Texas' Leadership Board of to advance prevention and treatment of lung disease.